Approval of a Pediatric, Patient-Friendly Oral Liquid Formulation

Nova Laboratories, a UK-based company, has received final marketing authorization from the European Medicines Agency (EMA) for Xromi (hydroxycarbamide), its treatment for Sickle Cell Disease (SCD). Xromi works by inhibiting ribonucleotide reductase (RNR), thereby promoting the production of fetal hemoglobin (HbF). The existing standard treatment, a capsule form of hydroxycarbamide, was difficult for infants and young children to swallow, resulting in poor compliance. Xromi has been developed as a 100 mg/ml oral liquid formulation, which significantly improves ease of administration and patient compliance. The EMA recognized the convenience and clinical benefits of this drug for pediatric patients and has granted final approval as a hybrid medicine.

Expanded Indication to Infants and Market Position

At the time of its initial approval, Xromi was indicated for children aged 2 years and older, but this has now been expanded to include infants aged 9 months and older. Because SCD causes progressive organ damage and acute pain from early infancy, early intervention is critical for improving long-term patient outcomes. This expanded indication allows Nova Laboratories to exclusively target the market for infants under 1 year of age, who have previously been underserved. This aligns perfectly with the global trend of early diagnosis and treatment in the pediatric rare disease market.

Benefit from Safety Issues with Competing Drugs

Recently, the SCD treatment market has undergone significant changes due to safety and efficacy issues with competing drugs. Novartis' Adakveo received a recommendation for withdrawal of marketing authorization from the EMA due to a lack of efficacy, and Pfizer's Oxbryta also decided to voluntarily withdraw globally due to safety concerns, including an increased risk of death. As a result, the market has seen a departure of high-priced drugs that were previously considered reliable, and Xromi, a traditional hydroxycarbamide-based drug with proven safety and long-term clinical data, has become a more viable alternative and a more established standard of care. The demand for a safe and proven oral liquid formulation is expected to increase rapidly, and Nova Laboratories' market share is expected to grow rapidly in the short term.

Price Competitiveness and Cost-Effectiveness for Healthcare Systems

Vertex and CRISPR Therapeutics have developed innovative gene therapies such as Casgevy, but their high prices, in the millions of dollars, severely limit patient access. In contrast, Xromi offers both an affordable price and proven clinical value, giving it a significant advantage in cost-benefit analyses conducted by healthcare authorities in various European countries. In negotiations for reimbursement listing in national health insurance systems, Xromi is expected to secure reimbursement more quickly than existing high-priced treatments, thereby significantly expanding access to treatment. A reasonable pricing policy and the convenience of a liquid formulation will be key to reducing the burden on national healthcare budgets and expanding prescriptions.

Future Growth Prospects and Market Size of Sickle Cell Disease

The global SCD treatment market is expected to reach approximately $3.75 billion in 2025 and is projected to grow at a rapid rate of about 15% per year, reaching approximately $16 billion in 2035. In particular, the pediatric and infant segment, which is targeted by Xromi, is considered a key area where early preventive treatment is most urgently needed. Nova Laboratories, a privately held company, is expected to consolidate its exclusive position in Europe with Xromi and then explore expansion into other regions with high unmet needs, such as North America and Asia-Pacific. This expanded European approval is a major achievement that will maximize the company's long-term pipeline value and provide a strong financial foundation for the development of subsequent pediatric formulations.